Belite Bio (BLTE) Competitors $65.10 +1.51 (+2.37%) Closing price 03:59 PM EasternExtended Trading$65.10 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLTE vs. ROIV, RGC, ELAN, RVMD, GRFS, TGTX, NUVL, CRSP, RYTM, and LNTHShould you be buying Belite Bio stock or one of its competitors? The main competitors of Belite Bio include Roivant Sciences (ROIV), Regencell Bioscience (RGC), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), CRISPR Therapeutics (CRSP), Rhythm Pharmaceuticals (RYTM), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Belite Bio vs. Its Competitors Roivant Sciences Regencell Bioscience Elanco Animal Health Revolution Medicines Grifols TG Therapeutics Nuvalent CRISPR Therapeutics Rhythm Pharmaceuticals Lantheus Belite Bio (NASDAQ:BLTE) and Roivant Sciences (NASDAQ:ROIV) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation. Which has more risk & volatility, BLTE or ROIV? Belite Bio has a beta of -1.5, suggesting that its share price is 250% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Which has better valuation & earnings, BLTE or ROIV? Belite Bio has higher earnings, but lower revenue than Roivant Sciences. Belite Bio is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBelite BioN/AN/A-$36.14M-$1.36-47.87Roivant Sciences$29.05M266.86-$171.98M-$0.25-45.62 Does the media favor BLTE or ROIV? In the previous week, Roivant Sciences had 7 more articles in the media than Belite Bio. MarketBeat recorded 10 mentions for Roivant Sciences and 3 mentions for Belite Bio. Roivant Sciences' average media sentiment score of 0.85 beat Belite Bio's score of 0.64 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is BLTE or ROIV more profitable? Belite Bio has a net margin of 0.00% compared to Roivant Sciences' net margin of -225.71%. Roivant Sciences' return on equity of -14.76% beat Belite Bio's return on equity.Company Net Margins Return on Equity Return on Assets Belite BioN/A -32.07% -30.91% Roivant Sciences -225.71%-14.76%-13.69% Do insiders & institutionals believe in BLTE or ROIV? 0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 7.9% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend BLTE or ROIV? Belite Bio currently has a consensus target price of $96.67, indicating a potential upside of 48.49%. Roivant Sciences has a consensus target price of $16.50, indicating a potential upside of 44.67%. Given Belite Bio's higher possible upside, analysts plainly believe Belite Bio is more favorable than Roivant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Belite Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.25 SummaryRoivant Sciences beats Belite Bio on 11 of the 16 factors compared between the two stocks. Get Belite Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLTE vs. The Competition Export to ExcelMetricBelite BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.07B$3.04B$5.59B$9.53BDividend YieldN/A2.39%4.71%4.03%P/E Ratio-47.8721.2227.9619.93Price / SalesN/A200.39389.5465.88Price / CashN/A42.5736.3258.75Price / Book13.798.268.375.77Net Income-$36.14M-$55.06M$3.25B$259.10M7 Day Performance4.48%-3.99%-2.50%-3.41%1 Month Performance12.82%13.86%7.98%8.53%1 Year Performance33.51%4.02%34.65%15.75% Belite Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLTEBelite Bio1.7755 of 5 stars$65.10+2.4%$96.67+48.5%+28.3%$2.07BN/A-47.8710ROIVRoivant Sciences2.5589 of 5 stars$11.35-1.7%$16.50+45.4%+6.9%$7.85B$29.05M-45.40860Positive NewsUpcoming EarningsRGCRegencell Bioscience0.2628 of 5 stars$13.80-8.3%N/AN/A$7.44BN/A0.0010Positive NewsELANElanco Animal Health3.269 of 5 stars$14.59-2.2%$16.17+10.8%+11.4%$7.41B$4.43B19.729,000Positive NewsRVMDRevolution Medicines4.4631 of 5 stars$37.26-1.7%$68.91+84.9%-19.4%$7.06B$11.58M-9.32250Upcoming EarningsGRFSGrifols3.4436 of 5 stars$10.09-0.1%$10.30+2.1%+36.2%$6.94B$7.81B8.6223,822News CoverageGap UpTGTXTG Therapeutics3.6517 of 5 stars$35.99-2.5%$43.80+21.7%+78.3%$5.86B$329M149.96290Positive NewsUpcoming EarningsNUVLNuvalent3.4085 of 5 stars$81.94+0.7%$119.60+46.0%+0.1%$5.85BN/A-18.6740Positive NewsCRSPCRISPR Therapeutics2.519 of 5 stars$63.75-1.6%$71.31+11.9%+0.9%$5.59B$37.31M-14.10460News CoverageUpcoming EarningsGap UpRYTMRhythm Pharmaceuticals3.1521 of 5 stars$85.68-0.9%$91.93+7.3%+75.7%$5.50B$130.13M-30.49140Upcoming EarningsInsider TradeLNTHLantheus4.627 of 5 stars$72.41-0.7%$131.20+81.2%-35.3%$5.05B$1.53B20.57700Positive NewsUpcoming EarningsAnalyst Revision Related Companies and Tools Related Companies ROIV Alternatives RGC Alternatives ELAN Alternatives RVMD Alternatives GRFS Alternatives TGTX Alternatives NUVL Alternatives CRSP Alternatives RYTM Alternatives LNTH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BLTE) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredStrange Investment Secret Predicts Market's Next Move?A strange market signal discovered before the Great Depression has predicted nearly every major financial even...Weiss Ratings | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belite Bio, Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Belite Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
